Why Farbe Firma is the Top Manufacturer of Aminophylline Injection
- Maulik Sudani
- 11 hours ago
- 6 min read
Last Updated: May 31, 2026
TL;DR: Aminophylline Injection — a sterile parenteral solution of the methylxanthine bronchodilator aminophylline (the theophylline-ethylenediamine complex, roughly 80% theophylline), supplied most commonly as 25 mg/mL in 10 mL ampoules (250 mg/10 mL) — is a long-established intravenous bronchodilator for acute severe asthma and acute exacerbations of chronic obstructive pulmonary disease that do not respond adequately to inhaled bronchodilators, and for apnoea of prematurity in the neonatal unit. Because theophylline has a narrow therapeutic index (target plasma 10–20 mg/L) and aminophylline is a strongly alkaline solution, its safe use depends on precise assay, tight pH control and freedom from particulate matter. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Aminophylline Injection at our Gujarat, India facility and supplies it to respiratory and critical-care services, neonatal units, hospital tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Methylxanthine bronchodilator (theophylline-ethylenediamine) — Aminophylline Injection is the long-established intravenous bronchodilator and respiratory stimulant for acute severe asthma, acute COPD exacerbations not responding to inhaled therapy, and apnoea of prematurity, acting through phosphodiesterase inhibition and adenosine-receptor antagonism to relax bronchial smooth muscle and stimulate respiratory drive.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified clear-glass ampoule filling lines, dedicated control of a strongly alkaline, narrow-therapeutic-index solution whose assay and pH must be held batch to batch, with validated terminal sterilisation and container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, respiratory-programme and hospital tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Aminophylline Injection Demands a Premium Manufacturer
Aminophylline Injection has held a place on the emergency and respiratory shelf for decades. It is the intravenous bronchodilator that emergency physicians and intensivists reach for when a patient in acute severe asthma or a severe COPD exacerbation is not responding adequately to nebulised beta-agonists and ipratropium, when bronchospasm is life-threatening and an additional mechanism of action is needed. In the neonatal unit it is used in a quite different role — as a respiratory stimulant for apnoea of prematurity, where small, carefully calculated doses help drive the immature respiratory centre. In each setting aminophylline is given as a slow intravenous injection or a controlled infusion, and the patient depends on the dose being delivered accurately and the solution being free of particles.
That clinical reality places real demands on the manufacturer. Aminophylline is not a forgiving molecule. It is a complex of theophylline with ethylenediamine — the ethylenediamine is present specifically to make theophylline soluble enough for a parenteral solution — and the resulting injection is strongly alkaline, with a pH typically around 8.6 to 9.0. Theophylline itself has a famously narrow therapeutic index: the target plasma concentration is 10–20 mg/L, and toxicity (arrhythmia, seizures) can appear not far above that, so the labelled content of every ampoule must be exact. The alkaline solution is also incompatible with many acidic drugs and reacts with carbon dioxide from the air, so formulation, filling and sealing must protect it end to end. Choosing an Aminophylline Injection manufacturer that treats assay precision, pH control, particulate-free filling and container-closure integrity as core engineering disciplines is what protects the asthma, COPD and neonatal patient at the bedside.
What Sets a World-Class Aminophylline Injection Manufacturer Apart
A world-class manufacturer of Aminophylline Injection invests in three areas that weaker suppliers underfund: exact assay and content uniformity for a narrow-therapeutic-index drug where every milligram matters, rigorous control of the alkaline pH and freedom from precipitation so that no particulate reaches the patient's vein, and tender-ready dossier support for a product procured almost entirely through hospital, respiratory-programme and ministry-of-health channels. It starts with the active — pharmacopoeial-grade aminophylline (with its defined theophylline-to-ethylenediamine ratio) sourced from qualified, audited API makers, with full impurity profiling, water-content control and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and packaging then have to preserve both the molecule and the dose. The bulk solution is compounded under controlled conditions at the alkaline pH at which the theophylline-ethylenediamine complex stays in solution, protected from atmospheric carbon dioxide that would otherwise drive theophylline out of solution, adjusted for total theophylline content, sterile-filtered and filled under ISO Class 5 air into clear-glass ampoules, then terminally sterilised on validated cycles. In-process and release testing confirm theophylline content by HPLC, pH within the narrow specification, clarity and freedom from precipitated theophylline crystals, and the characteristic clear, colourless-to-faintly-yellow appearance. Container-closure integrity is verified on every batch, and stability is tracked under ICH Q1A long-term and accelerated conditions and ICH Q1B photostability protocols.
Quality Systems Behind Every Aminophylline Injection
Every Farbe Firma Aminophylline Injection batch is released only after a full stack of quality checks: theophylline assay against USP, BP, IP or EP reference standards, ethylenediamine content, related-substances and degradation-product profiling by HPLC, pH within the alkaline specification, osmolarity, clarity and absence of crystalline precipitate, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity and fill-volume verification for the 10 mL (250 mg) ampoule format at 25 mg/mL. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because aminophylline is a narrow-therapeutic-index drug in a chemically sensitive alkaline solution, we treat assay precision and pH as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light and air through its primary and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Aminophylline Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across respiratory, critical-care, anaesthesia, anti-infective, neonatal and supportive-care categories. For Aminophylline Injection specifically, we supply 25 mg/mL solution in 10 mL (250 mg) clear-glass ampoules under WHO-GMP conditions, with country-specific formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the assay-validation and stability data package — ready to hand for registration.
Our CDMO services scale cleanly from single-hospital and neonatal-unit supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, related-substances and assay-method validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Aminophylline Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, method-validation data, artwork, production slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through assay precision, pH and CO2 control, particulate management, terminal-sterilisation qualification, container-closure and stability choices in real detail. For an intravenous bronchodilator given to patients in acute respiratory distress and to premature neonates, where dose accuracy directly governs safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Aminophylline Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Aminophylline Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified clear-glass ampoule filling lines, qualified water-for-injection systems, validated terminal sterilisation cycles and continuous environmental monitoring.
Which strength and pack size of Aminophylline Injection do you supply?
Our standard presentation is 25 mg/mL in 10 mL clear-glass ampoules (250 mg per ampoule). Custom fill volumes and country-specific pack configurations are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations for Aminophylline Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay-method and related-substances validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the quality and safety of Aminophylline Injection?
We hold the solution at its specified alkaline pH while protecting it from atmospheric carbon dioxide, control theophylline content by HPLC against pharmacopoeial standards, verify clarity and freedom from crystalline precipitate, run particulate, endotoxin and sterility testing, verify container-closure integrity on every batch, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Aminophylline Injection contract manufacturing?
MOQs vary by fill volume, label complexity and dossier requirements. For the 250 mg/10 mL presentation we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments